Table 4.

Results by multivariate analysis.

		OR	95% CI	p-value
ESAS (ref: score ≤ 3)
- Pain
Gender (ref: Women)	Men	0.5	(0.3–0.6)	<0.0001
Age class (ref: < 70 years)	≥ 70	0.7	(0.5–0.9)	0.0149
Tumor site (ref: Other)	GU	2.3	(1.2–4.6)	0.0155
- Nausea
Gender (ref: Women)	Men	0.7	(0.4–1.0)	0.0276
Age class (ref: < 70 years)	≥ 70	0.6	(0.4–0.9)	0.0103
- Depression
Gender (ref: Women)	Men	0.6	(0.4–0.8)	0.0008
- Anxiety
Gender (ref: Women)	Men	0.6	(0.4–0.8)	0.0016
- Appetite loss
Gender (ref: Women)	Men	0.6	(0.5–0.8)	0.0031
- Wellbeing
Gender (ref: Women)	Men	0.5	(0.4–0.7)	<0.0001
Tumor site (ref: Other)	GU	2.4	(1.2–4.8)	0.0111
- Dyspnea
Tumor site (ref: Other)	GI	0.5	(0.3–1.0)	0.0440
MUST (ref: score 0–1)
Gender (ref: Women)	Men	0.7	(0.5–1.0)	0.0311
PROGNOSIS AWARENESS (ref: Absent)
Gender (ref: Women)	Men	0.6	(0.4–0.8)	0.0011
Age class (ref: < 70 years)	≥ 70	0.6	(0.5–0.9)	0.0049
SAT^ AT THE END OF LIFE (ref: > 30 days)
Age class (ref: < 70 years)	≥ 70	0.4	(0.2–0.7)	0.0006
UNPLANNED ER* VISITS (ref: No)
Gender (ref: Women)	Men	1.6	(1.1–2.3)	0.0110
PLACE OF DEATH (ref: Hospital)
Gender (ref: Women)	Men	0.6	(0.4–1.0)	0.0294
Age class (ref: < 70 years)	≥ 70	2.1	(1.3–3.3)	0.0028
SURVIVAL		HR
Age class (ref: < 70 years)	≥ 70	0.8	(0.7–0.9)	0.0072
Tumor site (ref: Other)	GI	1.5	(1.1–2.0)	0.0099

^SAT, systemic anticancer therapy.

*ER, emergency room.

OR, odds ratio; HR, hazard ratio.